How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

211 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Topical treatments for seborrhoeic dermatitis of the scalp – need for more evidence

to inhibit the inflammatory reaction. In general there is limited evidence available on the treatment of seborrhoeic dermatitis of the scalp with topical agents. This is unfortunate as it is such a common condition. Only ketoconazole and ciclopirox were studied in multiple RCT’s that met the inclusion criteria for our recent systematic overview. For other topical treatments such as bifonazole, selenium sulfide, tar shampoo and corticosteroids the evidence was much sparser. For each type of topical (...) be considered in every patient that is disturbed by the symptoms of his condition. This way the physical complaints, and also the social consequences, can be decreased. One of the more established treatments for seborrhoeic dermatitis of the scalp is ketoconazole. The studies confirmed that it appears to be beneficial for both clearance of the initial flare and maintenance of the improved clinical condition. In this update of the review, ciclopirox was the only other treatment that also seemed

2015 BMJ Clinical Evidence Blog

62. Network Meta-Analysis of Onychomycosis Treatments. (PubMed)

was significantly superior to all topicals except efinaconazole 10% nail solution. Itraconazole 200 mg was significantly superior to all topical treatments, while fluconazole 150-450 mg, efinaconazole 10% nail solution, tavaborole 5% nail solution, ciclopirox nail lacquer 8%, terbinafine nail solution, and amorolfine 5% nail lacquer were significantly superior to placebo.Newly developed topicals have improved the odds ratios (ORs) of mycological cure, yet these ORs were not significantly greater than

Full Text available with Trip Pro

2016 Skin appendage disorders

63. Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole (PubMed)

in the literature and none that were successfully treated. Here we present a case of successfully treated onychomycosis caused by P. lilacinus with efinaconazole and tavaborole in a patient who had failed treatment with oral fluconazole, itraconazole, terbinafine, and topical ciclopirox and naftifine.

Full Text available with Trip Pro

2016 Skin appendage disorders

64. The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis

, 2017 Last Verified: April 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Additional relevant MeSH terms: Layout table for MeSH terms Onychomycosis Tinea Dermatomycoses Skin Diseases, Infectious Infection Mycoses Nail Diseases Skin Diseases Ciclopirox Antifungal Agents Anti-Infective Agents

2015 Clinical Trials

65. Treatment of Onychomycosis - a Clinical Study. (PubMed)

on disease severity, patients were grouped into groups with SCIO values: 6-9, and 12-16. These groups were randomly subdivided to 5 subgroups according to the given treatment protocols: fluconazole 150 mg 1x weekly, itraconazole continual therapy, itraconazole pulse therapy, terbinafine 250 mg/d, and terbinafine + ciclopirox 8% lacquer, respectively. The cure rate was evaluated at the end of 48 week.The obtained cure rates according to the above mentioned protocols were: 92.30%, 81.81%, 83.33%, 90.90

Full Text available with Trip Pro

2015 Medical archives (Sarajevo, Bosnia and Herzegovina)

67. Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview. (PubMed)

Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview. Three systemic agents commonly are used for the treatment of onychomycosis. Until the introduction of ciclopirox in 1999, these were the only FDA-approved therapeutic options for managing these infections. With the recent approval of two new topical antifungal agents-efinaconazole in the azole class, and tavaborole, a unique boron-containing medication- clinicians and patients have an improved roster of medications

2015 Seminars in Cutaneous Medicine and Surgery

68. ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis: Characterization of Antifungal Activity and Nail Penetration. (PubMed)

of ME1111, a novel antifungal agent, along with comparator drugs, including ciclopirox, amorolfine, terbinafine, and itraconazole. ME1111 showed potent antifungal activity against Trichophyton rubrum and Trichophyton mentagrophytes (the major etiologic agents of onychomycosis) strains isolated in Japan and reference fungal strains with an MIC range of 0.12 to 0.5 mg/liter and an MIC50 and MIC90 of 0.5 mg/liter for both. Importantly, none of the tested isolates showed an elevated ME1111 MIC. Moreover (...) , the antifungal activity of ME1111 was minimally affected by 5% wool keratin powder in comparison to the other antifungals tested. The ME1111 solution was able to penetrate human nails and inhibit fungal growth in a dose-dependent manner according to the TurChub assay. In contrast, 8% ciclopirox and 5% amorolfine nail lacquers showed no activity under the same conditions. ME1111 demonstrated approximately 60-fold-greater selectivity in inhibition of Trichophyton spp. than of human cell lines. Our findings

Full Text available with Trip Pro

2015 Antimicrobial Agents and Chemotherapy

69. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections (PubMed)

properties of gallium compounds, 5-fluorouracil, ciclopirox, diflunisal, and some other FDA-approved drugs and argue that their repurposing for the treatment of bacterial infections, including those that are multidrug resistant, is a feasible strategy.

Full Text available with Trip Pro

2015 Frontiers in microbiology

70. In Vitro Antifungal Activity of ME1111, a New Topical Agent for Onychomycosis, against Clinical Isolates of Dermatophytes. (PubMed)

= 4) following repeated exposure to ME1111. Our data show that the MIC90 of ME1111 against dermatophyte strains was 0.25 μg/ml, which was equivalent to that of the comparators amorolfine and ciclopirox (0.25 and 0.5 μg/ml, respectively). ME1111 was fungicidal at clinically achievable concentrations against dermatophytes, and its MFC90s against Trichophyton rubrum and Trichophyton mentagrophytes were 8 μg/ml, comparable to those of ciclopirox. Furthermore, ME1111, as well as ciclopirox, did

Full Text available with Trip Pro

2015 Antimicrobial Agents and Chemotherapy

71. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species. (PubMed)

In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species. The in vitro activities of 11 antifungal drugs against 68 Scopulariopsis and Microascus strains were investigated. Amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, ketoconazole, miconazole, posaconazole, voriconazole, and ciclopirox showed no or poor antifungal effect. The best activities were exhibited by terbinafine and caspofungin, where the MIC and MEC (minimal

Full Text available with Trip Pro

2015 Antimicrobial Agents and Chemotherapy

72. Is there any evidence on what treatment is available for children aged under 12 with fungal nail infection?

itraconazole, fluconazole, and terbinafine, and the topical nail lacquers ciclopirox and amorolfine are not approved for this indication. More data are needed on the use of these antifungal agents for the treatment of onychomycosis in children.” 1. 2. 3. Answered 8 October 2013 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2013 TRIP Answers

73. Potential of ergosterol synthesis inhibitors to cause (cross)resistance in Trichophyton rubrum. (PubMed)

of resistance to terbinafine, itraconazole, amorolfine, and ciclopirox in T. rubrum. Results demonstrated that naturally occurring mutants were isolated at a frequency of 10(-7) for itraconazole and 10(-9) for terbinafine and amorolfine. To mimic conditions of body sites in which low drug levels are reached during therapy, T. rubrum was propagated for 10 transfers in media containing subinhibitory drug concentrations. Resistance to itraconazole, terbinafine, and amorolfine emerged at a higher frequency than (...) was seen with spontaneous mutation. Itraconazole-resistant mutants also showed decreased susceptibility to amorolfine as well as to terbinafine, and amorolfine-resistant mutants were also less susceptible to terbinafine. No mutant resistant to ciclopirox was isolated, suggesting no propensity of T. rubrum to develop resistance to this drug. How different drug mechanisms of action can influence the onset of resistance is discussed.

Full Text available with Trip Pro

2014 Antimicrobial Agents and Chemotherapy

74. Silicon phthalocyanine (Pc) 4 phototoxicity in Trichophyton rubrum. (PubMed)

Silicon phthalocyanine (Pc) 4 phototoxicity in Trichophyton rubrum. Trichophyton rubrum is the leading pathogen that causes long-lasting skin and nail dermatophyte infections. Currently, topical treatment consists of terbinafine for the skin and ciclopirox for the nails, whereas systemic agents, such as oral terbinafine and itraconazole, are also prescribed. These systemic drugs have severe side effects, including liver toxicity. Topical therapies, however, are sometimes ineffective. This led

Full Text available with Trip Pro

2014 Antimicrobial Agents and Chemotherapy

75. Luliconazole Demonstrates Potent In vitro Activity against the Dermatophytes Recovered from Patients with Onychomycosis. (PubMed)

Luliconazole Demonstrates Potent In vitro Activity against the Dermatophytes Recovered from Patients with Onychomycosis. The in vitro activities of luliconazole, amorolfine, ciclopirox, and terbinafine were determined against 320 dermatophyte isolates from large toenails of onychomycosis patients enrolled into an ongoing phase 2b/3 clinical study. The geometric mean MIC for luliconazole was 0.00022 μg/ml against all isolates, compared to 0.0194 to 0.3107 μg/ml for the three other agents

Full Text available with Trip Pro

2014 Antimicrobial Agents and Chemotherapy

76. Therapies for Onychomycosis: A Systematic Review and Network Meta-Analysis of Mycological Cure. (PubMed)

, and data were analyzed using network meta-analysis. Terbinafine, 250 mg, therapy was significantly superior to all treatments except itraconazole, 400 mg, pulse therapy; itraconazole, 200 mg, therapy was significantly superior to fluconazole and the topical treatments; and fluconazole, efinaconazole, ciclopirox, terbinafine nail solution, and amorolfine treatments were significantly superior to only placebo. These results support the superiority of 12-week continuous terbinafine, 250 mg, therapy

2014 Journal of the American Podiatric Medical Association

77. Lateral Drug Diffusion in Human Nails (PubMed)

Lateral Drug Diffusion in Human Nails The main objective of the current work is to demonstrate the process of passive lateral diffusion in the human nail plate and its effect on the passive transungual permeation of antifungal drug ciclopirox olamine (CPO). A water soluble dye, methyl red sodium salt (MR) was used to visualize the process of lateral diffusion using a novel suspended nail experiment. The decline in concentration of CPO correlates with that of concentration of MR from

Full Text available with Trip Pro

2014 AAPS PharmSciTech

78. Paronychia (Overview)

. Daniel CR 3rd, Daniel MP, Daniel J, Sullivan S, Bell FE. Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen. Cutis . 2004 Jan. 73(1):81-5. . Media Gallery Classic presentation of paronychia, with erythema and pus surrounding the nail bed. In this case, the paronychia was due to infection after a hangnail was removed. In this case of paronychia, no pus or fluctuance is involved in the nail bed itself. Typical appearance of paronychia. Depicted

2014 eMedicine.com

79. Onychomycosis (Overview)

of topical and systemic treatment increases the cure rate. Adjunctive surgical measures may also be used. Topical therapy for onychomycosis is as follows: Ciclopirox olamine 8% nail lacquer solution Amorolfine or bifonazole/urea (available outside the United States) Efinaconazole 10% topical solution (the first FDA-approved topical triazole for toenail onychomycosis) Tavaborole 0.5% topical solution, an oxaborole solution (boron-containing compound) Can be used in WSO and DLSO limited to the distal nail (...) as and . Previous References Andre J, Achten G. Onychomycosis. Int J Dermatol . 1987 Oct. 26(8):481-90. . Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol . 1998 Oct. 139(4):567-71. . Bohn M, Kraemer K. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc . 2000 Nov-Dec. 90(10):491-4. . Leverone AP, Guimarães DA, Bernardes-Engemann AR, Orofino-Costa R. Laser treatment of onychomycosis due to Neoscytalidium dimidiatum: An open prospective

2014 eMedicine.com

80. Erythropoietic Porphyria (Overview)

1103274-overview Diseases & Conditions Diseases & Conditions 2002 1389981-overview Diseases & Conditions Diseases & Conditions 2002 957765-overview Diseases & Conditions Diseases & Conditions 2010 loprox-penlac-ciclopirox-topical-343484 Drugs Drugs Need a Curbside Consult? Share cases and questions with Physicians on Medscape consult.

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>